Neumora Therapeutics (NMRA) Depreciation & Amortization (CF) (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Depreciation & Amortization (CF) of $8000.0 for Q1 2026, down 94.9% year-over-year from $157000.0 in Q1 2025, and down 11.11% quarter-over-quarter from $9000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $8000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 94.9% year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $59000.0 (down 90.63% YoY), while the FY2025 annual figure was $208000.0, down 67.04% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $8000.0, down from $9000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $198000.0 in Q4 2023, with the low at $8000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $157000.0 (2024), against an average of $121428.6.
- The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) increased 29.41% in 2023, then tumbled 94.9% in 2026.
- Neumora Therapeutics' Depreciation & Amortization (CF) stood at $153000.0 in 2022, then grew by 29.41% to $198000.0 in 2023, then retreated by 20.71% to $157000.0 in 2024, then slumped by 94.27% to $9000.0 in 2025, then retreated by 11.11% to $8000.0 in 2026.
- Business Quant data shows NMRA's Depreciation & Amortization (CF) at $8000.0 in Q1 2026, $9000.0 in Q4 2025, and $23000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 157,000.00 |
| Mar 31, 2025 | 157,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | 156,000.00 |
| Sep 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Dec 31, 2023 | 198,000.00 |
| Dec 31, 2023 | 198,000.00 |